Cargando…

Cancer Gene Therapy Goes Viral: Viral Vector Platforms Come of Age

BACKGROUND: Since the advent of viral vector gene therapy in 1990s, cancer treatment with viral vectors promised to revolutionize the field of oncology. Notably, viral vectors offer a unique combination of efficient gene delivery and engagement of the immune system for anti-tumour response. Despite...

Descripción completa

Detalles Bibliográficos
Autor principal: Bezeljak, Urban
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sciendo 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8884858/
https://www.ncbi.nlm.nih.gov/pubmed/35148469
http://dx.doi.org/10.2478/raon-2022-0002
_version_ 1784660261374787584
author Bezeljak, Urban
author_facet Bezeljak, Urban
author_sort Bezeljak, Urban
collection PubMed
description BACKGROUND: Since the advent of viral vector gene therapy in 1990s, cancer treatment with viral vectors promised to revolutionize the field of oncology. Notably, viral vectors offer a unique combination of efficient gene delivery and engagement of the immune system for anti-tumour response. Despite the early potential, viral vector-based cancer treatments are only recently making a big impact, most prominently as gene delivery devices in approved CAR-T cell therapies, cancer vaccines and targeted oncolytic therapeutics. To reach this broad spectrum of applications, a number of challenges have been overcome – from our understanding of cancer biology to vector design, manufacture and engineering. Here, we take an overview of viral vector usage in cancer therapy and discuss the latest advancements. We also consider production platforms that enable mainstream adoption of viral vectors for cancer gene therapy. CONCLUSIONS: Viral vectors offer numerous opportunities in cancer therapy. Recent advances in vector production platforms open new avenues in safe and efficient viral therapeutic strategies, streamlining the transition from lab bench to bedside. As viral vectors come of age, they could become a standard tool in the cancer treatment arsenal.
format Online
Article
Text
id pubmed-8884858
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Sciendo
record_format MEDLINE/PubMed
spelling pubmed-88848582022-03-15 Cancer Gene Therapy Goes Viral: Viral Vector Platforms Come of Age Bezeljak, Urban Radiol Oncol Review BACKGROUND: Since the advent of viral vector gene therapy in 1990s, cancer treatment with viral vectors promised to revolutionize the field of oncology. Notably, viral vectors offer a unique combination of efficient gene delivery and engagement of the immune system for anti-tumour response. Despite the early potential, viral vector-based cancer treatments are only recently making a big impact, most prominently as gene delivery devices in approved CAR-T cell therapies, cancer vaccines and targeted oncolytic therapeutics. To reach this broad spectrum of applications, a number of challenges have been overcome – from our understanding of cancer biology to vector design, manufacture and engineering. Here, we take an overview of viral vector usage in cancer therapy and discuss the latest advancements. We also consider production platforms that enable mainstream adoption of viral vectors for cancer gene therapy. CONCLUSIONS: Viral vectors offer numerous opportunities in cancer therapy. Recent advances in vector production platforms open new avenues in safe and efficient viral therapeutic strategies, streamlining the transition from lab bench to bedside. As viral vectors come of age, they could become a standard tool in the cancer treatment arsenal. Sciendo 2022-02-11 /pmc/articles/PMC8884858/ /pubmed/35148469 http://dx.doi.org/10.2478/raon-2022-0002 Text en © 2022 Urban Bezeljak, published by Sciendo https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
spellingShingle Review
Bezeljak, Urban
Cancer Gene Therapy Goes Viral: Viral Vector Platforms Come of Age
title Cancer Gene Therapy Goes Viral: Viral Vector Platforms Come of Age
title_full Cancer Gene Therapy Goes Viral: Viral Vector Platforms Come of Age
title_fullStr Cancer Gene Therapy Goes Viral: Viral Vector Platforms Come of Age
title_full_unstemmed Cancer Gene Therapy Goes Viral: Viral Vector Platforms Come of Age
title_short Cancer Gene Therapy Goes Viral: Viral Vector Platforms Come of Age
title_sort cancer gene therapy goes viral: viral vector platforms come of age
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8884858/
https://www.ncbi.nlm.nih.gov/pubmed/35148469
http://dx.doi.org/10.2478/raon-2022-0002
work_keys_str_mv AT bezeljakurban cancergenetherapygoesviralviralvectorplatformscomeofage